Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 3, 1998, Pages 654-658

  Le Fichoux, Yves ^a   Rousseau, Déborah ^a   Ferrua, Bernard ^a   Ruette, Sandrine ^b   Lelièvre, Alain ^a   Grousson, Dominique ^b   Kubar, Joanna ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b Virbac SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VISCERAL LEISHMANIASIS;

EID: 0031895279     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.3.654     Document Type: Article

References (56)

1. Addy, M., and A. Nandy. 1992. Ten years of kala-azar in West Bengal. Part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull. W. H. O. 70:341-346.
2. Alvar, J., B. Gutierrez-Solar, I. Pachon, E. Calbacho, M. Ramirez, R. Valles, J. Guillen, C. Canavate, and C. Amela. 1996. AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin. Dermatol. 14:541-546.
3. Aronson, N., J. Jackson, G. Wortmann, and C. Oster. 1997. Sodium stibogluconate therapy for leishmaniasis: the experience of the american military 1989-1996, abstr. 374. Acta Parasitol. Turcica 21(Suppl. 1):177.
4. Beckers, T., R. Voegeli, and P. Hilgard. 1994. Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines. Eur. J. Cancer 30:2143-2150.
5. Ben Said, M., A. Mili, F. Amri, and H. Kharrat. 1997. Resistance to N-methylglucamine in tunisian visceral leishmaniasis children, abstr. 395. Acta Parasitai. Turcica 21(Suppl. 1):184.
6. 2+ concentration in a normal and a breast cancer cell line. Anticancer Res. 14:1549-1556.
7. Berkovic, D., U. Grunwald, W. Menzel, C. Unger, W. Hiddemann, and E. A. Fleer. 1995. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur. J. Cancer 31:2080-2085.
8. Bhaduri, A., and K. R. Santhamma. 1997. Leishmanial fumarate reductase is a new target for drug development: studies with a synthetic Lapachol, abstr. 403. Acta Parasitol. Turcica 21(Suppl. 1):187.
9. Bradley, D. J. 1987. Genetics of susceptibility and resistance in the vertebrate host, p. 551-577. In W. Peters, and R. Killick-Kendrick (ed.), The leishmaniasis in biology and medicine. Academic Press, London, United Kingdom.
10. Carter, K. C., A. B. Mullen, and A. J. Baillie. 1997. Treatment with a vesicular formulation of sodium stibogluconate (SSG) and immunity to homologous challenge with Leishmania donovani, abstr. 401. Acta Parasitol. Turcica 21(Suppl. 1):187.
11. Clive, S., and R. C. F. Leonard. 1996. Miltefosine in recurrent cutaneous breast cancer. Lancet 349:621-622.
12. Croft, S. L., D. Snowden, and V. Yardley. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1041-1047.
13. Davidson, R. N., L. di Martino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scotti, F. Raimondi, and A. Cascio. 1994. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Q. J. Med. 87:75-81.
14. Davidson, R. N., L. di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, F. Pempinello, S. Scotti, A. Cascio, E. Castagnola, and A. Maisto. 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22:938-943.
15. Dietze, R., E. P. Milan, J. D. Berman, M. Grogl, A. Falqueto, T. F. Feitosa, K. G. Luz, F. A. B. Suassuna, L. A. C. Marinho, and G. Ksionski. 1993. Treatment of Brazilian kala-azar with a short course of Amphocil® (amphotericin B cholesterol dispersion). Clin. Infect. Dis. 17:981-986.
16. Dietze, R., S. M. S. Fagundes, E. F. Brito, E. P. Milan, T. F. Feitosa, F. A. B. Suassuna, G. Fonschiffrey, G. Ksionski, and J. Dember. Treatment of kalaazar in Brazil with Amphocil® (amphotericin B cholesterol dispersion) for 5 days. Trans. R. Soc. Trop. Med. Hyg. 89:309-311.
17. Domingo, P., S. Ferrer, L. Kolle, C. Munoz, and P. Rodriguez. 1996. Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus. Arch. Intern. Med. 156:1029-1032.
18. Eue, I., R. Zeisig, and D. Arndt. 1995. Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U937 cells. J. Cancer Res. Clin. Oncol. 121:350-356.
19. Faraut-Gamnarelli, F., R. Piarroux, M. Deniau, B. Giusiano, P. Marty, M. Michel, B. Faugere, and H. Dumon. 1997. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate, abstr. 408. Acta Parasitol. Turcica 21(Suppl. 1):188.
20. Fleer, E. A., D. Berkovic, H. Eibl, and C. Unger. 1993. Investigations on the cellular uptake of hexadecylphosphocholine. Lipids 28:731-736.
21. Geilen, C. C., T. Wieder, A. Haase, W. Reutter, D. M. Morre, and D. J. Morre. 1994. Uptake, subcellular distribution and metabolism of the phospholipid analogue hexadecylphosphocholine in MDCK cells. Biochim. Biophys. Acta 1211:14-22.
22. Gradoni, L. 1996. Chemotherapy of leishmaniasis and trypanosomiasis. Curr. Opin. Infect. Dis. 9:435-438.
23. Hochhuth, C. H., K. Vehmeyer, H. Eibl, and C. Unger. 1992. Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol. 141:161-168.
24. Jeromino, S. M. B., R. M. Oliveira, S. Mackay, R. M. Costa, J. Sweet, E. T. Nascimento, K. G. Luz, M. Z. Fernandes, J. Jernigan, and R. D. Pearson. 1994. An urban outbreak of visceral leishmaniasis in Natal, Brazil. Trans. R. Soc. Trop. Med. Hyg. 88:386-388.
25. Kharazmi, A., M. Chen, L. Zhai, S. F. Nielsen, and S. B. Christensen. 1997. Discovery and development of oxygenated Chalconcs A5 potential novel antileishmanial agents, abstr. 371. Acta Parasitol. Turcica 21(Suppl. 1):176.
26. Kuhlencord, A., T. Maniera, H. Eibl, and C. Unger. 1992. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36:1630-1634.
27. Laguna, F., J. Torre-Cisneros, V. Moreno, J. L. Villanueva, and E. Valencia. 1995. Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 21:711-712.
28. Maly, K., F. Uberall, C. Schubert, E. Kindler, J. Stekar, H. Brachwitz, and H. H. Grunicke. 1995. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anti-Cancer Drug Des. 10:411-425.
29. Marschner, N., J. Kotting, H. Eibl, and C. Unger. 1992. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother. Pharmacol. 31:18-22.
30. McBride, M. O., M. Linney, R. N. Davidson, and J. N. Weber. 1995. Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate. Clin. Infect. Dis. 21:710. (Letter.)
31. Mullen, A., A. J. Baillie, O'Grady, and K. C. Carter. 1997. Comparison of the efficacy of a non-ionic surfactant vesicular formulation of sodium stibogluconate (SSG) in a hamster model of visceral leishmaniasis, abstr. 402. Acta Parasitol. Turcica 21(Suppl. 1):186.
32. Murray, H. W., H. Masur, and J. S. Keithly. 1982. Cell-mediated immune response in experimental visceral leishmaniasis. Correlation between resistance to L. donovani and lymphokine-generating capacity. J. Immunol. 129: 344-349.
33. Pearson, R. D., and A. de Queiroz Sousa. 1995. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22:1-13.
34. Peters, B. S., D. Fish, R. Golden, D. A. Evans, A. D. M. Bryceson, and A. J. Pinching. 1990. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q. J. Med. 77:1101-1111.
35. Planting, A. S., G. Stoter, and J. Verweij. 1993. Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur. J. Cancer. 29:518-519.
36. Pronk, L. C., A. S. Planting, R. Oosterom, T. E. Drogendijk, G. Stoter, and J. Verweij. 1994. Increases in leucocyte and platelet counts induced by the alkylphospholipid hexadecylphosphocholine. Eur. J. Cancer. 30:1019-1022.
37. Reitz, R. C., J. Kotting, C. Unger, and H. Eibl. 1992. Comparison of the tissue distribution of hexadecylphosphocholine and erucylphosphocholine. Prog. Exp. Tumor Res. 34:143-152.
38. Rousseau, D., Y. Le Fichoux, X. Stien, I. Suffia, B. Ferrua, and J. Kubar. 1997. Progression of visceral leishmaniasis due to Leishmania infantum in BALB/c mice is markedly slowed by prior infection with Trichinella spiralis. Infect. Immun. 65:4978-4983.
39. Russo, R., L. C. Nigro, S. Minniti, A. Montineri, L. Gradoni, L. Caldeira, and R. N. Davidson. 1996. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J. Infect. 32:133-137.
40. Stauber, L. A. 1958. Host resistance to the Khartoum strain of Leishmania donovani. Rice Inst. Pamphlets 45:80-83.
41. Steelant, W. F., E. A. Bruyneel, M. M. Mareel, and E. G. Van den Eeckhout. 1995. Capillary gas chromatography of hexadecylphosphocholine in Caco-2T cells and cell culture media. Anal. Biochem. 227:246-250.
42. Suffia, I., J. F. Quaranta, M. C. Eulalio, B. Ferrua, P. Marty, Y. Le Fichoux, and J. Kubar. 1995. Human T-cell activation by 14-and 18-kilodalton nuclear proteins of Leishmania infantum. Infect. Immun. 63:3765-3771.
43. Sundar, S., and H. W. Murray. 1996. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J. Infect. Dis. 173: 762-765.
44. Sundar, S., G. Horwith, and H. W. Murray. 1997. Cure of antimony-refractory Indian kala-azar with short-course, low-dose intravenous Amphotericin B Lipid Complex (AbLC) therapy, abstr. 375. Acta Parasitol. Turcica 21(Suppl. 1):177.
45. Thakur, C. P., A. K. Pandey, G. P. Sinha, S. Roy, K. Behbehani, and P. Olliaro. 1996. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome®) for visceral leishmaniasis in India: a randomized dose finding study. Trans. R. Soc. Trop. Med. Hyg. 90:319-322.
46. Theischen, M., N. Bornfeld, R. Becher, U. Kellner, and A. Wessing. 1993. Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium. Ger. J. Ophthalmol. 2:113-115.
47. Torres-Santos, E. C., D. L. Moreira, M. A. C. Kaplan, and B. Rossi-Bergmann. 1997. A chalcone isolated from the plant Piper aduncum is selectively toxic for Leishmania, abstr. 390. Acta Parasitol. Turcica 21(Suppl. 1):177-178.
48. Vehmeyer, K., P. Scheurich, H. Eibl, and C. Unger. 1991. Hexadecylphosphocholine-mediated enhancement of T-cell response to interleukin-2. Cell. Immunol. 137:232-238.
49. Verweij, J., A. Planting, M. Van der Burg, and G. Stoter. 1992. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J. Cancer Res. Clin. Oncol. 118:606-608.
50. Wieder, T., A. Haase, C. C. Geilen, and C. E. Orfanos. 1995. The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. Lipids 30:389-393.
51. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFNγ in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
52. World Health Organization. 1990. Antimonials: large-scale failure in leishmaniasis "alarming." Trop. Dis. Res. News 34:1, 7.
53. World Health Organization. 1991. AIDS, leishmaniasis dangers of clash highlighted. Trop. Dis. Res. News 36:1, 11.
54. Zeisig, R., I. Eue, M. Kosch, I. Fichtner, and D. Arndt. 1996. Preparation and properties of sterically stabilized hexadecylphosphocholine (miltefosine)-liposomes and influence of this modification on macrophage activation. Biochim. Biophys. Acta. 1283:177-184.
55. Zeisig, R., M. Rudolf, I. Eue, and D. Arndt. 1995. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 121:69-75.
56. Zijlstra, E. E., A. M. El-Hassan, A. Ismael, and H. W. Ghalib. 1994. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am. J. Trop. Med. Hyg. 51:826-836.